External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

Key points (machine generated)<ul><li>Sanofi is acquiring Vigil Neuroscience for $8 per share, with an additional $2 contingent value right (CVR) based on VG-3927's commercial sale by 2035.</li><li>Vigil Neuroscience is currently priced at $7.98, presenting a low-risk opportunity for investors to benefit from the CVR as the deal is expected to close soon.</li><li>The CVR's payout is uncertain due to VG-3927's early clinical trial status for Alzheimer's disease, despite Sanofi's strong financial position and minimal regulatory hurdles.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Sanofi is acquiring Vigil Neuroscience for $8 per share, with an additional $2 contingent value right (CVR) based on VG-3927's commercial sale by 2035.Vigil Neuroscience is currently priced at $7.98, presenting a low-risk opportunity for investors to benefit from the CVR as the deal is expected to close soon.The CVR's payout is uncertain due to VG-3927's early clinical trial status for Alzheimer's disease, despite Sanofi's strong financial position and minimal regulatory hurdles.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Vigil Neuroscience Inc (VIGL) - Monday, Jul 7, 2025

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Vigil Neuroscience / Equity Capital Markets

<ul>
<li>Clinical-Stage biotech company, <a href="https://www.smartkarma.com/entities/vigil-neuroscience-inc" target="_blank" data-smartkarma-citation="entities:35125:1" rel="noopener">Vigil Neuroscience Inc (VIGL US)</a> plans to offer 7 million shares at a price range of $15 to $17 per share in its upcoming IPO.</li>
<li>The company is expected to price the IPO on January 6 and trade on January 7 on NASDAQ under the ticker symbol VIGL.</li>
<li>The company developing antibody therapies for neurodegenerative diseases. Its lead candidate VGL101 is in phase 1 clinical trial, with topline data expected in H2 2022.</li>
</ul>


Clinical-Stage biotech company, Vigil Neuroscience Inc (VIGL US) plans to offer 7 million shares at a price range of $15 to $17 per share in its upcoming IPO.
The company is expected to price the IPO on January 6 and trade on January 7 on NASDAQ under the ticker symbol VIGL.
The company developing antibody therapies for neurodegenerative diseases. Its lead candidate VGL101 is in phase 1 clinical trial, with topline data expected in H2 2022.


Vigil Neuroscience (VIGL US) IPO: Early-Stage First-Of-Its-Class Pipeline Makes It a Risky Bet

United States

Vigil Neuroscience, Inc. operates as a biotechnology company. The Company focuses on discovering and developing novel therapeutics in basic science and human genetics of microglia. Vigil Neuroscience serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vigil Neuroscience (VIGL US)

Vigil Neuroscience Inc (VIGL) - Monday, Jul 7, 2025

Sanofi is acquiring Vigil Neuroscience for $8 per share plus a potential $2 CVR, offering investors a low-risk opportunity amid uncertainties in...

Value Investors Club (VIC)

Vigil Neuroscience (VIGL US) IPO: Early-Stage First-Of-Its-Class Pipeline Makes It a Risky Bet

The company plans to raise $112 million through its IPO. Vigil is a clinical-stage biotech company, whose lead drug candidate has just entered into...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)